The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $182.62

Today's change0.00 0.00%
Updated December 24 1:00 PM -5GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $182.62

Today's change0.00 0.00%
Updated December 24 1:00 PM -5GMT. Delayed by at least 15 minutes.

Spdr S&P Biotech Etf closed at (U.S.)$182.62.

Shares have lost 0.32% over the last five days, but sit 4.75% below their 52-week high. This security has outperformed the S&P 500 by 26.69% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $182.62
  • High--
  • Low--
  • Bid / Ask(U.S.) $182.81 / (U.S.) $188.88
  • YTD % change+40.26%
  • Volume536
  • Average volume (10-day)772,417
  • Average volume (1-month)574,688
  • Average volume (3-month)503,118
  • 52-week range(U.S.) $115.31 to (U.S.) $191.72
  • Beta1.12
  • Trailing P/E3.88×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $2.00
  • Dividend yield1.10%
  • Trailing EPS(U.S.) $47.08
Updated December 24 1:00 PM -5GMT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q2/2014Q4/2013Q2/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201406/30/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013Dec 31, 201212/31/2012
Revenue10323
Total other revenue--------
Total revenue10323
Gross profit--------
Total cost of revenue--------
Total operating expense2211
Selling / general / administrative2211
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income8111
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax141200125-11
Income after tax141200125-11
Income tax, total0000
Net income141200125-11
Total adjustments to net income--------
Net income before extra. items141200125-11
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items141200125-11
Inc. avail. to common incl. extra. items141200125-11
Diluted net income141200125-11
Dilution adjustment------0
Diluted weighted average shares7897
Diluted EPS excluding extraordinary itemsvalue per share21.0726.0113.83-1.50
Dividends per sharevalue per share0.940.130.090.20
Diluted normalized EPSvalue per share21.0726.0113.83-1.50